Cardiology · LMNA-Related Cardiomyopathy

Diagnosis and Genetic Subtypes of LMNA-CM

At a Glance

LMNA-CM is assessed with EKG and Holter monitoring, a heart ultrasound, cardiac MRI, and genetic testing. A pathogenic LMNA variant can guide targeted testing for relatives, but variant categories only suggest group-level risks and cannot predict one person’s course.

Getting a diagnosis of LMNA-related cardiomyopathy (LMNA-CM) is often a multi-step process. Because the “LMNA gene” can affect both the heart’s structure and its electrical timing, doctors look at several different types of evidence to confirm the condition ^[1]^[2].

The Diagnostic Toolkit

Diagnosis usually involves a combination of tests that look at the “wiring” and the “pumping” of your heart:

EKG and Holter Monitors: These check for conduction disease (slow signals) or “short circuits” like atrial fibrillation. In LMNA-CM, these electrical changes often show up years before the heart muscle begins to weaken ^[3]^[4].
Echocardiogram: A standard ultrasound to measure your ejection fraction (pumping power). However, a “normal” result here does not mean the disease is absent, as the electrical system can be affected first ^[5].
Cardiac MRI: This is a powerful tool used to find fibrosis (microscopic scar tissue). Seeing scar tissue on an MRI—specifically something called late gadolinium enhancement (LGE)—can help your doctor understand your risk for heart rhythm issues even if your pumping power is still strong ^[6]^[7].
Genetic Testing: A blood or saliva test looks for a pathogenic or likely pathogenic variant in the LMNA gene, which confirms the molecular diagnosis ^[8]. Note: A Variant of Uncertain Significance (VUS) does not establish a diagnosis and cannot be used for predictive family testing. A negative genetic panel does not entirely rule out inherited heart disease.

Understanding Your Genetic Subtype

Not all LMNA mutations are the same. Your genetic report will likely use technical terms to describe your specific “variant.” These categories are probabilistic cohort associations that can help inform discussions, but they do not guarantee how the disease will behave in any one individual:

Variant Type	What it means	General Outlook
Truncating / Splice	The protein may be cut short or misread and might not function normally ^[2].	Often associated in large cohorts with an earlier onset of heart block and a higher risk of heart rhythm issues ^[9]^[2].
Missense	A single “letter” in the DNA is swapped, like a typo in a word ^[10].	Extremely variable; some cause mild disease in later life, while others can be more aggressive ^[11]^[12].
Ig-Domain (IgD)	The mutation is in a specific C-terminal structural domain of the protein ^[13].	Some cohort studies suggest these variants may be associated with a unique pattern of scarring and rhythm risks ^[13]^[14].

Overlapping Conditions (Phenotypes)

The LMNA gene is active in many parts of the body, not just the heart. Some people with LMNA-CM may also have “overlapping” symptoms in other tissues:

Skeletal Muscle: Some variants cause Emery-Dreifuss Muscular Dystrophy (EDMD). This can lead to weakness in the shoulders and hips, or “contractures”—where joints like the elbows or ankles become stiff and hard to straighten ^[15]^[16].
Lipodystrophy: A rare overlap where the body has trouble storing fat in certain areas (like the limbs) but accumulates it in others. This can lead to metabolic issues like insulin resistance or early-onset diabetes ^[17]^[18].

Cascade Screening: Protecting Your Family

Because LMNA-CM is autosomal dominant, there is a 50% chance of passing the gene to each child ^[19]^[20].

Cascade screening is the process of testing your first-degree relatives (parents, siblings, and children) for the specific variant found in you ^[1]. This is vital because family members can have the gene and be at risk for sudden heart issues even if they feel perfectly healthy ^[5].

A good testing sequence involves obtaining the laboratory report, meeting with a genetic counselor, and offering targeted testing to relatives. If a relative tests positive, they enter age-appropriate cardiology screening. If a relative receives a reliable negative result for the known familial pathogenic variant—interpreted by a genetics professional—they may be released from frequent cardiac screening, assuming they have no symptoms or abnormal cardiac findings ^[21]. Evaluation for children should be personalized and often involves a pediatric cardiologist and a genetic counselor ^[22]^[23].

Common questions in this guide

How is LMNA-related cardiomyopathy diagnosed?

LMNA-CM is usually evaluated with several tests. An EKG and Holter monitor look for conduction problems and rhythm disorders, an echocardiogram measures pumping function, and a cardiac MRI can show scar tissue. Genetic testing can confirm the molecular diagnosis when it finds a pathogenic or likely pathogenic LMNA variant, but a normal echocardiogram alone does not rule out the condition.

What does a VUS in the LMNA gene mean?

A variant of uncertain significance, or VUS, means that current evidence is not enough to say whether the LMNA change causes disease. A VUS does not establish an LMNA-CM diagnosis and should not be used for predictive testing of healthy relatives. A negative genetic panel also does not completely rule out inherited heart disease, so discuss the results with a genetics professional.

Can a normal echocardiogram rule out LMNA-CM?

No. LMNA-related disease can affect the heart’s electrical system before it weakens the heart’s pumping function, so an echocardiogram may look normal early on. EKG or Holter monitoring and, when appropriate, cardiac MRI can provide additional information.

What do different LMNA variant types mean for my risk?

Truncating or splice variants are associated in large groups with earlier heart block and higher rhythm risk, while missense variants can range from mild later-onset disease to more aggressive disease. Ig-domain variants may have particular patterns of scarring and rhythm risk in some studies. These are group-level associations and cannot predict exactly what will happen to one person.

Can an LMNA variant affect muscles or metabolism?

Some LMNA variants are linked to Emery-Dreifuss muscular dystrophy, which can cause weakness in the shoulders and hips and stiff joints called contractures. Others can be associated with lipodystrophy, abnormal fat storage, insulin resistance, or early-onset diabetes. Ask your care team whether a baseline muscle exam or CK blood test is appropriate.

Should my relatives get genetic testing for LMNA-CM?

LMNA-CM is usually inherited in an autosomal dominant pattern, so a person with the variant has a 50% chance of passing it to each child. Parents, siblings, and children can be offered targeted testing for the family’s known pathogenic variant, even if they feel well. Relatives who test positive generally need age-appropriate cardiac screening, while a reliable negative result may allow less frequent screening after review by a genetics professional.

Curated prompts to bring to your next appointment.

1.Which 'genetic subtype' is my LMNA mutation (truncating or missense), and what does that tell us about my risk level?
2.My genetic report mentions a 'VUS'—does that mean my diagnosis is still uncertain?
3.Are my current EKG and Holter monitor results showing any 'silent' conduction disease?
4.Since we found this in me, can you help me set up 'cascade screening' for my siblings and children?
5.Should I have a 'baseline' muscle exam or blood test (like CK levels) to check for overlapping muscle issues?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

LMNA-CM can first appear as conduction disease, heart block, or atrial fibrillation, sometimes years before the heart’s pumping function declines.
Diagnosis combines EKG or Holter monitoring, echocardiography, cardiac MRI for fibrosis, and genetic testing for a pathogenic or likely pathogenic LMNA variant.
A variant of uncertain significance does not establish LMNA-CM or support predictive testing of relatives, and a negative gene panel does not fully exclude inherited heart disease.
Truncating, splice, missense, and Ig-domain variants show different group-level associations, but no subtype guarantees an individual outcome.
Because inheritance is autosomal dominant, each child may have a 50% chance of inheriting a familial LMNA variant, making targeted testing and age-appropriate cardiac screening important for relatives.

References (23)

1
Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.
Hasselberg NE, Haland TF, Saberniak J, et al.
European heart journal 2018; (39(10)):853-860 doi:10.1093/eurheartj/ehx596.
PMID: 29095976
2
Gene-Based Risk Stratification for Cardiac Disorders in LMNA Mutation Carriers.
Nishiuchi S, Makiyama T, Aiba T, et al.
Circulation. Cardiovascular genetics 2017; (10(6)) doi:10.1161/CIRCGENETICS.116.001603.
PMID: 29237675
3
Effect of Occurrence of Lamin A/C (LMNA) Genetic Variants in a Cohort of 101 Consecutive Apparent "Lone AF" Patients: Results and Insights.
Pessente GD, Sacilotto L, Calil ZO, et al.
Frontiers in cardiovascular medicine 2022; (9()):823717 doi:10.3389/fcvm.2022.823717.
PMID: 35449878
4
Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy.
Tremblay-Gravel M, Ichimura K, Picard K, et al.
Circulation. Genomic and precision medicine 2023; (16(1)):e003480 doi:10.1161/CIRCGEN.121.003480.
PMID: 36548481
5
LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician.
Rosario KF, Karra R, Amos K, et al.
Journal of cardiac failure 2023; (29(12)):1657-1666 doi:10.1016/j.cardfail.2023.08.016.
PMID: 37659618
6
Late gadolinium enhancement role in arrhythmic risk stratification of patients with LMNA cardiomyopathy: results from a long-term follow-up multicentre study.
Peretto G, Barison A, Forleo C, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2020; (22(12)):1864-1872 doi:10.1093/europace/euaa171.
PMID: 32995851
7
Meta-analysis of the role of cardiac magnetic resonance in laminopathy.
Shahshenas S, Anissian A, Jalali Nadoushan M, Soltanipur M
Archives of cardiovascular diseases 2026; (119(5)):357-367 doi:10.1016/j.acvd.2026.02.003.
PMID: 41966904
8
Use of machine learning to classify high-risk variants of uncertain significance in lamin A/C cardiac disease.
Bennett JS, Gordon DM, Majumdar U, et al.
Heart rhythm 2022; (19(4)):676-685 doi:10.1016/j.hrthm.2021.12.019.
PMID: 34958940
9
Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy.
Bhaskaran A, Ben Yaou R, Helms AS, et al.
JAMA cardiology 2025; (10(9)):896-903 doi:10.1001/jamacardio.2025.2069.
PMID: 40601341
10
The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope.
Al-Saaidi RA, Rasmussen TB, Birkler RID, et al.
European journal of heart failure 2018; (20(10)):1404-1412 doi:10.1002/ejhf.1241.
PMID: 29943882
11
Lamin A/C-Related Cardiac Disease: Late Onset With a Variable and Mild Phenotype in a Large Cohort of Patients With the Lamin A/C p.(Arg331Gln) Founder Mutation.
Hoorntje ET, Bollen IA, Barge-Schaapveld DQ, et al.
Circulation. Cardiovascular genetics 2017; (10(4)) doi:10.1161/CIRCGENETICS.116.001631.
PMID: 28790152
12
Lamin mutation location predicts cardiac phenotype severity: combined analysis of the published literature.
Captur G, Arbustini E, Syrris P, et al.
Open heart 2018; (5(2)):e000915 doi:10.1136/openhrt-2018-000915.
PMID: 30402260
13
Variant-Specific Late Gadolinium Enhancement Patterns Influence Clinical Outcomes in LMNA-Related Cardiomyopathy.
Castrichini M, Garmany R, Siontis KC, et al.
Journal of the American Heart Association 2025; (14(15)):e041230 doi:10.1161/JAHA.124.041230.
PMID: 40689545
14
Domain-specific association of single-nucleotide variants in the LMNA gene with the phenotypic expression of dilated cardiomyopathy.
Zhuo W, Jiang Z, Xun M, et al.
International journal of cardiology 2025; (424()):133043 doi:10.1016/j.ijcard.2025.133043.
PMID: 39923945
15
Cardiac diseases as a predictor warning of hereditary muscle diseases. The case of laminopathies.
D'Ambrosio P, Petillo R, Torella A, et al.
Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2019; (38(2)):33-36.
PMID: 31309180
16
Clinical aspects of Emery-Dreifuss muscular dystrophy.
Madej-Pilarczyk A
Nucleus (Austin, Tex.) 2018; (9(1)):268-274 doi:10.1080/19491034.2018.1462635.
PMID: 29633897
17
Complex effects of laminopathy mutations on nuclear structure and function.
Ho R, Hegele RA
Clinical genetics 2019; (95(2)):199-209 doi:10.1111/cge.13455.
PMID: 30280378
18
A Novel Lamin A Mutant Responsible for Congenital Muscular Dystrophy Causes Distinct Abnormalities of the Cell Nucleus.
Barateau A, Vadrot N, Vicart P, et al.
PloS one 2017; (12(1)):e0169189 doi:10.1371/journal.pone.0169189.
PMID: 28125586
19
Lamin A/C Cardiomyopathy: Implications for Treatment.
Chen SN, Sbaizero O, Taylor MRG, Mestroni L
Current cardiology reports 2019; (21(12)):160 doi:10.1007/s11886-019-1224-7.
PMID: 31773301
20
Troponin T Assessment Allows for Identification of Mutation Carriers among Young Relatives of Patients with LMNA-Related Dilated Cardiomyopathy.
Chmielewski P, Kowalik I, Truszkowska G, et al.
Journal of clinical medicine 2024; (13(11)) doi:10.3390/jcm13113164.
PMID: 38892874
21
Clinical Features of LMNA-Related Cardiomyopathy in 18 Patients and Characterization of Two Novel Variants.
Ferradini V, Cosma J, Romeo F, et al.
Journal of clinical medicine 2021; (10(21)) doi:10.3390/jcm10215075.
PMID: 34768595
22
Characterization of cardiac involvement in children with LMNA-related muscular dystrophy.
Cesar S, Campuzano O, Cruzalegui J, et al.
Frontiers in cell and developmental biology 2023; (11()):1142937 doi:10.3389/fcell.2023.1142937.
PMID: 36968203
23
Cardiac and Neuromuscular Features of Patients With LMNA-Related Cardiomyopathy.
Peretto G, Di Resta C, Perversi J, et al.
Annals of internal medicine 2019; (171(7)):458-463 doi:10.7326/M18-2768.
PMID: 31476771

This page explains LMNA-CM diagnosis, genetic variants, and family screening for educational purposes. Your cardiologist and genetics professional should interpret your results and recommend testing or monitoring for your specific situation.

Get notified when new evidence is published on Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents